Immatics NV (IMTX) Stock Price, Quote & News

Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid t...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 7071 5397 0

Fax: 49 7071 5397 900

Website: www.immatics.com

Address:

Paul-Ehrlich-Strasse 15, Tübingen, Germany

RemoteInvestor Oct. 21 at 2:17 PM

$IMTX market realizing the content of yesterday's PR!

0 · Reply

RemoteInvestor Oct. 20 at 9:01 PM

$IMTX ESMO news! https://investors.immatics.com/news-releases/news-release-details/immatics-highlights-compelling-anti-tumor-activity-anzu-cel-0

0 · Reply

lukasgx Oct. 20 at 8:16 PM

$IMTX any PR based ESMO today presentation ?

0 · Reply

RemoteInvestor Oct. 17 at 1:43 PM

$IMTX I would not sell this right before ESMO in Berlin! BTW: Stop-losses are not a good idea...

0 · Reply

RemoteInvestor Oct. 17 at 1:38 PM

$IMTX up we go! Glad I have added. Life changing science!

0 · Reply

RemoteInvestor Oct. 17 at 12:07 PM

$IMTX "Sell the ESMO news" + bad market... I am considering adding. Any thoughts?

1 · Reply

RemoteInvestor Oct. 15 at 7:47 PM

$IMTX at ESMO!

0 · Reply

RemoteInvestor Oct. 15 at 4:02 PM

$IMTX are we presenting at ESMO next week?

1 · Reply

RemoteInvestor Oct. 15 at 12:48 PM

Binary event stocks! In crazy times with high volatility these are my biotech favs: $IMTX (oncology) $SLS (oncology) $VTGN (mental diseases)

0 · Reply

SaluteYourShorts Oct. 13 at 7:11 PM

$IMTX hmmm

0 · Reply

Immatics Appoints Amie Krause as Chief People Officer

Oct 20, 2025, 10:30 AM EDT - 7 days ago

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

Oct 10, 2025, 10:25 AM EDT - 17 days ago

Immatics: Multiple Clinical Catalysts In Q4'25 And 2026

Aug 13, 2025, 7:00 AM EDT - 2 months ago

Immatics Announces Second Quarter 2025 Financial Results and Business Update

May 31, 2025, 8:00 AM EDT - 5 months ago

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

May 13, 2025, 7:00 AM EDT - 5 months ago

Immatics Announces First Quarter 2025 Financial Results and Business Update

Apr 23, 2025, 10:00 AM EDT - 6 months ago

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Mar 28, 2025, 1:02 PM EDT - 7 months ago

Immatics N.V.: Trading Below Cash, But Not Without Reason

Mar 27, 2025, 7:00 AM EDT - 7 months ago

Immatics Announces Full Year 2024 Financial Results and Business Update

Nov 18, 2024, 7:00 AM EST - 1 year ago

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

Nov 8, 2024, 5:00 PM EST - 1 year ago

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Oct 11, 2024, 9:11 PM EDT - 1 year ago

Immatics: A Promising TCR Pipeline

Oct 10, 2024, 8:50 PM EDT - 1 year ago

Immatics Announces Pricing of $150 Million Public Offering

Oct 10, 2024, 1:33 PM EDT - 1 year ago

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Immatics Announces Proposed $150 Million Public Offering

Oct 10, 2024, 6:30 AM EDT - 1 year ago

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Sep 16, 2024, 5:25 AM EDT - 1 year ago

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Immatics Announces Second Quarter 2024 Financial Results and Business Update

May 14, 2024, 7:00 AM EDT - 1 year ago

Immatics Announces First Quarter 2024 Financial Results and Business Update

Apr 27, 2024, 10:32 AM EDT - 1 year ago

Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Feb 3, 2024, 7:56 AM EST - 1 year ago

Immatics: Pioneering TCR Therapies In The Fight Against Cancer

Jan 17, 2024, 8:30 PM EST - 1 year ago

Immatics Announces Pricing of $175 Million Public Offering

Jan 17, 2024, 4:01 PM EST - 1 year ago

Immatics Announces Proposed Public Offering

Nov 14, 2023, 7:00 AM EST - 2 years ago

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Nov 8, 2023, 7:00 AM EST - 2 years ago

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Oct 24, 2023, 7:00 AM EDT - 2 years ago

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

Oct 9, 2023, 1:33 AM EDT - 2 years ago

Analyzing Immatics' Multi-Faceted Investment Case

Sep 12, 2023, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

PLX

Sep 11, 2023, 8:59 AM EDT - 2 years ago

Immatics shares rise on Moderna cancer collaboration

MRNA

Sep 11, 2023, 7:32 AM EDT - 2 years ago

Moderna, Immatics to work jointly on cancer vaccines

MRNA

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

MRNA

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Moderna & Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

MRNA

Aug 17, 2023, 7:00 AM EDT - 2 years ago

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

Jul 24, 2023, 6:21 PM EDT - 2 years ago

Immatics: Additional Gains Possible Q4 Of 2023 With Data Update Of IMA203

Jul 24, 2023, 10:00 AM EDT - 2 years ago

Immatics Is Increasingly Becoming Interesting

Jul 24, 2023, 7:56 AM EDT - 2 years ago

Immatics shares jump after investment from Bristol Myers Squibb

BMY

Jul 24, 2023, 7:00 AM EDT - 2 years ago

Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

May 16, 2023, 7:00 AM EDT - 2 years ago

Immatics Announces First Quarter 2023 Financial Results and Business Update

May 2, 2023, 7:00 AM EDT - 2 years ago

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

May 1, 2023, 7:00 AM EDT - 2 years ago

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

Mar 21, 2023, 7:31 AM EDT - 2 years ago

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Nov 17, 2022, 7:00 AM EST - 3 years ago

Immatics Announces Third Quarter 2022 Financial Results and Business Update

Oct 10, 2022, 7:37 AM EDT - 3 years ago

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

Oct 10, 2022, 7:36 AM EDT - 3 years ago

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

Sep 10, 2022, 3:06 AM EDT - 3 years ago

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

Aug 23, 2022, 7:00 AM EDT - 3 years ago

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

RemoteInvestor Oct. 21 at 2:17 PM

$IMTX market realizing the content of yesterday's PR!

0 · Reply

RemoteInvestor Oct. 20 at 9:01 PM

$IMTX ESMO news! https://investors.immatics.com/news-releases/news-release-details/immatics-highlights-compelling-anti-tumor-activity-anzu-cel-0

0 · Reply

lukasgx Oct. 20 at 8:16 PM

$IMTX any PR based ESMO today presentation ?

0 · Reply

RemoteInvestor Oct. 17 at 1:43 PM

$IMTX I would not sell this right before ESMO in Berlin! BTW: Stop-losses are not a good idea...

0 · Reply

RemoteInvestor Oct. 17 at 1:38 PM

$IMTX up we go! Glad I have added. Life changing science!

0 · Reply

RemoteInvestor Oct. 17 at 12:07 PM

$IMTX "Sell the ESMO news" + bad market... I am considering adding. Any thoughts?

1 · Reply

RemoteInvestor Oct. 15 at 7:47 PM

$IMTX at ESMO!

0 · Reply

RemoteInvestor Oct. 15 at 4:02 PM

$IMTX are we presenting at ESMO next week?

1 · Reply

RemoteInvestor Oct. 15 at 12:48 PM

Binary event stocks! In crazy times with high volatility these are my biotech favs: $IMTX (oncology) $SLS (oncology) $VTGN (mental diseases)

0 · Reply

SaluteYourShorts Oct. 13 at 7:11 PM

$IMTX hmmm

0 · Reply

ScrotusMagnum Oct. 13 at 3:50 PM

$APLX $IMTX $SPY in case you haven’t noticed, $WTI is in play. Its probably going to be halted with these 30% moves. CEO bought $5 M worth of shares last week in the open market. Buy WTI stock and WTI crude – both will be enormously profitable eventually.

0 · Reply

Biotech_Beast Oct. 10 at 2:32 PM

$IMTX Has multiple readouts in Q4'25, including data at ESMO on October 20. The company's cell therapy has advantages over $IOVA's lifileucel, although only applies to 40-50% of advanced melanoma patients. https://seekingalpha.com/article/4829111-immatics-multiple-clinical-catalysts-in-q425-and-2026

1 · Reply

estatebuyersmia Oct. 9 at 10:33 PM

$FBIO $IMTX THANK YOU CHATGPT

1 · Reply

BobBijawklah Oct. 9 at 7:21 PM

$IMTX gladi bought this at 5 and change sold half of my position rest is free and clear should have bought more. Looks like its going to be aquired if i had to guess. Probably 15-20 dollar range.

0 · Reply

OhioTrader Oct. 9 at 1:29 AM

$IMTX scorched earth baby!

0 · Reply

JJPlus7 Oct. 8 at 7:07 PM

What do you folks know about Immatics $IMTX ? It's made a nice run since 9/10 when it was sitting at $5.91

2 · Reply

Robin8877 Oct. 8 at 6:45 PM

$IMTX This one just keeps on going! I should have bought more.

1 · Reply

RemoteInvestor Oct. 8 at 5:32 PM

$IMTX great move over 10$ today! No obvious news... Still driven by new M&A CFO?

0 · Reply

OptionRunners Oct. 8 at 4:19 PM

$IMTX Buyer of the January 16th 2026 $5/$15 call spreads 8,500 times for $5.20

0 · Reply

RunnerSignals Oct. 3 at 8:27 PM

Market Warriors Rise 💥 From red to green $RKLB $ARBE $HOUS $HUM $IMTX showed the fighting spirit today!

0 · Reply

NVDAMillionaire Oct. 2 at 1:49 PM

$IMTX Excellent article that nails exactly where IMTX stands right now. So if you want to update your IMTX knowledge or get acquainted with IMTX, this is a must read. https://beyondspx.com/quote/IMTX/analysis/immatics-precision-oncology-unlocking-solid-tumor-potential-with-tcr-engineered-therapies-nasdaq-imtx

2 · Reply

RamenLives Oct. 1 at 5:35 PM

$IMTX Just curious, if a BO happens, what is a reasonable expectation of share price? IMO $30 seem about right.

2 · Reply

Market Cap	1.24B
Revenue (ttm)	168.63M
Net Income (ttm)	16.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	9.77%
Debt to Equity Ratio	0.00

Volume	244,188
Avg Vol	930,986
Day's Range	N/A - N/A
Shares Out	121.55M
Stochastic %K	30%
Beta	1.22
Analysts	Strong Sell
Price Target	$15.62